FOSCARNET SODIUM Drug Patent Profile
✉ Email this page to a colleague
When do Foscarnet Sodium patents expire, and what generic alternatives are available?
Foscarnet Sodium is a drug marketed by Amneal, Avet Lifesciences, Beijing, Fresenius Kabi Usa, Gland Pharma Ltd, and Hospira. and is included in six NDAs.
The generic ingredient in FOSCARNET SODIUM is foscarnet sodium. There are seven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the foscarnet sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Foscarnet Sodium
A generic version of FOSCARNET SODIUM was approved as foscarnet sodium by FRESENIUS KABI USA on January 29th, 2021.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FOSCARNET SODIUM?
- What are the global sales for FOSCARNET SODIUM?
- What is Average Wholesale Price for FOSCARNET SODIUM?
Summary for FOSCARNET SODIUM
| US Patents: | 0 |
| Applicants: | 6 |
| NDAs: | 6 |
| Finished Product Suppliers / Packagers: | 7 |
| Raw Ingredient (Bulk) Api Vendors: | 69 |
| Clinical Trials: | 24 |
| Patent Applications: | 4 |
| DailyMed Link: | FOSCARNET SODIUM at DailyMed |
Recent Clinical Trials for FOSCARNET SODIUM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Cttq | Phase 4 |
| Peking University People's Hospital | Phase 4 |
| City of Hope Medical Center |
Pharmacology for FOSCARNET SODIUM
| Drug Class | Pyrophosphate Analog DNA Polymerase Inhibitor |
| Mechanism of Action | Chelating Activity DNA Polymerase Inhibitors |
Medical Subject Heading (MeSH) Categories for FOSCARNET SODIUM
Anatomical Therapeutic Chemical (ATC) Classes for FOSCARNET SODIUM
US Patents and Regulatory Information for FOSCARNET SODIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amneal | FOSCARNET SODIUM | foscarnet sodium | INJECTABLE;INJECTION | 216602-001 | Mar 1, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Fresenius Kabi Usa | FOSCARNET SODIUM | foscarnet sodium | INJECTABLE;INJECTION | 212483-001 | Jan 29, 2021 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Avet Lifesciences | FOSCARNET SODIUM | foscarnet sodium | INJECTABLE;INJECTION | 213807-001 | Jun 5, 2023 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Beijing | FOSCARNET SODIUM | foscarnet sodium | INJECTABLE;INJECTION | 213987-001 | Nov 29, 2023 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hospira | FOSCARNET SODIUM | foscarnet sodium | INJECTABLE;INJECTION | 077174-001 | May 31, 2005 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Gland Pharma Ltd | FOSCARNET SODIUM | foscarnet sodium | INJECTABLE;INJECTION | 213001-001 | Apr 21, 2021 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
